CRYOPORT, INC. Selling, General and Administrative Expense
CRYOPORT, INC. (CYRX) reported Selling, General and Administrative Expense of $28.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- CRYOPORT, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $28.01M, a 4.10% increase year-over-year.
- CRYOPORT, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $27.62M, a 26.11% increase year-over-year.
- CRYOPORT, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $27.28M, a 2.88% decline year-over-year.
- CRYOPORT, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $26.73M, a 0.25% increase year-over-year.
- CRYOPORT, INC. selling, general and administrative expense for fiscal 2025 was $102.82M, a 6.37% decline from fiscal 2024.
- CRYOPORT, INC. selling, general and administrative expense for fiscal 2024 was $109.81M, a 1.43% increase from fiscal 2023.
- CRYOPORT, INC. selling, general and administrative expense for fiscal 2023 was $108.26M, a 9.82% decline from fiscal 2022.
- CRYOPORT, INC. selling, general and administrative expense for fiscal 2022 was $120.06M, a 23.05% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.01M 10-Q · filed 2026-08-06 | $55.63M 10-Q · filed 2026-08-06 | $82.91M derived: sum of 3 quarters · filed 2026-08-06 | $109.64M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $27.62M 10-Q · filed 2026-05-05 | $54.90M derived: sum of 2 quarters · filed 2026-05-05 | $81.63M derived: sum of 3 quarters · filed 2026-05-05 | $108.54M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $27.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $54.01M derived: sum of 2 quarters · filed 2026-03-05 | $80.92M derived: sum of 3 quarters · filed 2026-08-06 | $102.82M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $26.73M 10-Q · filed 2025-11-06 | $53.64M derived: sum of 2 quarters · filed 2026-08-06 | $75.54M 10-Q · filed 2025-11-06 | $103.63M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $26.91M 10-Q · filed 2026-08-06 | $48.81M 10-Q · filed 2026-08-06 | $76.89M derived: sum of 3 quarters · filed 2026-08-06 | $103.56M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $21.90M 10-Q · filed 2026-05-05 | $24.19M 10-Q · filed 2025-05-08 | $49.98M derived: sum of 2 quarters · filed 2026-05-05 | $76.65M derived: sum of 3 quarters · filed 2026-05-05 | $103.89M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $28.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $54.75M derived: sum of 2 quarters · filed 2026-03-05 | $81.99M derived: sum of 3 quarters · filed 2026-03-05 | $109.81M 10-K · filed 2026-03-05 | $148.98M 10-K · filed 2025-03-07 | |||
| 2024-09-30 | $26.67M 10-Q · filed 2025-11-06 | $37.65M 10-Q · filed 2024-11-07 | $53.90M derived: sum of 2 quarters · filed 2025-11-06 | $81.72M 10-Q · filed 2025-11-06 | $111.92M 10-Q · filed 2024-11-07 | $81.92M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-06-30 | $27.24M 10-Q · filed 2025-08-12 | $35.96M 10-Q · filed 2024-08-08 | $55.06M 10-Q · filed 2025-08-12 | $74.27M 10-Q · filed 2024-08-08 | $55.25M derived: sum of 3 quarters · filed 2026-03-05 | $91.28M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-03-31 | $27.82M 10-Q · filed 2025-05-08 | $38.30M 10-Q · filed 2024-05-08 | $28.02M derived: sum of 2 quarters · filed 2026-03-05 | $64.04M derived: sum of 3 quarters · filed 2026-03-05 | $102.84M derived: sum of 4 quarters · filed 2026-03-05 | |||
| 2023-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $36.22M derived: sum of 2 quarters · filed 2026-03-05 | $75.02M derived: sum of 3 quarters · filed 2026-03-05 | $108.26M 10-K · filed 2026-03-05 | $146.88M 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $36.02M 10-Q · filed 2024-11-07 | $74.83M derived: sum of 2 quarters · filed 2024-11-07 | $108.07M 10-Q · filed 2024-11-07 | $140.70M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-06-30 | $38.80M 10-Q · filed 2024-08-08 | $72.04M 10-Q · filed 2024-08-08 | $104.68M derived: sum of 3 quarters · filed 2025-03-07 | $134.91M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-03-31 | $33.24M 10-Q · filed 2024-05-08 | $65.88M derived: sum of 2 quarters · filed 2025-03-07 | $96.11M derived: sum of 3 quarters · filed 2025-03-07 | $126.67M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2022-12-31 | $32.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $62.87M derived: sum of 2 quarters · filed 2025-03-07 | $93.43M derived: sum of 3 quarters · filed 2025-03-07 | $120.06M 10-K · filed 2025-03-07 | ||||
| 2022-09-30 | $30.23M 10-Q · filed 2023-11-09 | $60.80M derived: sum of 2 quarters · filed 2023-11-09 | $87.42M 10-Q · filed 2023-11-09 | $115.01M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-06-30 | $30.56M 10-Q · filed 2023-08-09 | $57.19M 10-Q · filed 2023-08-09 | $84.77M derived: sum of 3 quarters · filed 2024-03-13 | $108.67M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-03-31 | $26.62M 10-Q · filed 2023-05-04 | $54.21M derived: sum of 2 quarters · filed 2024-03-13 | $78.11M derived: sum of 3 quarters · filed 2024-03-13 | $102.80M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2021-12-31 | $27.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $51.49M derived: sum of 2 quarters · filed 2024-03-13 | $76.17M derived: sum of 3 quarters · filed 2024-03-13 | $97.56M 10-K · filed 2024-03-13 | ||||
| 2021-09-30 | $23.90M 10-Q · filed 2022-11-04 | $48.59M derived: sum of 2 quarters · filed 2022-11-04 | $69.98M 10-Q · filed 2022-11-04 | $96.22M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $24.69M 10-Q · filed 2022-08-04 | $46.08M 10-Q · filed 2022-08-04 | $72.32M derived: sum of 3 quarters · filed 2023-02-28 | $86.80M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $21.39M 10-Q · filed 2022-05-05 | $47.63M derived: sum of 2 quarters · filed 2023-02-28 | $62.11M derived: sum of 3 quarters · filed 2023-02-28 | $71.14M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $26.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $40.72M derived: sum of 2 quarters · filed 2023-02-28 | $49.75M derived: sum of 3 quarters · filed 2023-02-28 | $56.86M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $14.48M 10-Q · filed 2021-11-04 | $23.50M derived: sum of 2 quarters · filed 2021-11-04 | $30.61M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $9.03M 10-Q · filed 2021-08-06 | $16.14M 10-Q · filed 2021-08-06 | ||||||
| 2020-03-31 | $7.11M 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | $31.29M 10-K · filed 2022-02-28 | |||||||
| 2015-12-31 | $2.84M 10-Q · filed 2016-02-11 | $4.99M derived: sum of 2 quarters · filed 2016-02-11 | $7.02M 10-Q · filed 2016-02-11 | $9.00M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2015-09-30 | $2.16M 10-Q · filed 2015-11-16 | $4.18M 10-Q · filed 2015-11-16 | $6.16M derived: sum of 3 quarters · filed 2015-11-16 | $7.65M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2015-06-30 | $2.03M 10-Q · filed 2015-08-06 | $4.00M derived: sum of 2 quarters · filed 2015-08-06 | $5.50M derived: sum of 3 quarters · filed 2016-02-11 | $7.01M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2015-03-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-19 | $3.47M derived: sum of 2 quarters · filed 2016-02-11 | $4.98M derived: sum of 3 quarters · filed 2016-02-11 | $6.41M 10-K · filed 2015-05-19 | ||||
| 2014-12-31 | $1.49M 10-Q · filed 2016-02-11 | $3.00M derived: sum of 2 quarters · filed 2016-02-11 | $4.43M 10-Q · filed 2016-02-11 | $5.77M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-09-30 | $1.51M 10-Q · filed 2015-11-16 | $2.94M 10-Q · filed 2015-11-16 | $4.28M derived: sum of 3 quarters · filed 2015-11-16 | $5.58M derived: sum of 4 quarters · filed 2015-11-16 | ||||
| 2014-06-30 | $1.43M 10-Q · filed 2015-08-06 | $2.77M derived: sum of 2 quarters · filed 2015-08-06 | $4.07M derived: sum of 3 quarters · filed 2015-08-06 | $5.31M derived: sum of 4 quarters · filed 2015-08-06 | ||||
| 2014-03-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-19 | $2.64M derived: sum of 2 quarters · filed 2015-05-19 | $3.88M derived: sum of 3 quarters · filed 2015-05-19 | $5.11M 10-K · filed 2015-05-19 | ||||
| 2013-12-31 | $1.31M 10-Q · filed 2015-02-05 | $2.55M derived: sum of 2 quarters · filed 2015-02-05 | $3.77M 10-Q · filed 2015-02-05 | $3.77M derived: sum of 4 quarters · filed 2015-02-05 | ||||
| 2013-09-30 | $1.24M 10-Q · filed 2014-11-12 | $2.46M 10-Q · filed 2014-11-12 | $2.46M derived: sum of 3 quarters · filed 2014-11-12 | $3.86M derived: sum of 4 quarters · filed 2014-11-12 | ||||
| 2013-06-30 | $1.22M 10-Q · filed 2014-07-31 | $1.22M derived: sum of 2 quarters · filed 2014-07-31 | $2.62M derived: sum of 3 quarters · filed 2014-07-31 | $3.96M derived: sum of 4 quarters · filed 2014-07-31 | ||||
| 2013-03-31 | $1.41K 10-K · filed 2013-06-25 | $1.39M derived: sum of 2 quarters · filed 2014-02-13 | $2.74M derived: sum of 3 quarters · filed 2014-02-13 | $5.41M 10-K · filed 2014-06-25 | ||||
| 2012-12-31 | $1.39M 10-Q · filed 2014-02-13 | $2.73M derived: sum of 2 quarters · filed 2014-02-13 | $4.00M 10-Q · filed 2014-02-13 | $4.00M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-09-30 | $1.34M 10-Q · filed 2013-11-18 | $2.61M 10-Q · filed 2013-11-18 | $2.61M derived: sum of 3 quarters · filed 2013-11-18 | $2.61M derived: sum of 4 quarters · filed 2013-11-18 | ||||
| 2012-06-30 | $1.27M 10-Q · filed 2013-08-14 | $1.27M derived: sum of 2 quarters · filed 2013-08-14 | $1.27M derived: sum of 3 quarters · filed 2013-08-14 | $1.27M derived: sum of 4 quarters · filed 2013-08-14 | ||||
| 2012-03-31 | $1.17K 10-K · filed 2013-06-25 | $2.91K derived: sum of 2 quarters · filed 2013-06-25 | $4.48K derived: sum of 3 quarters · filed 2013-06-25 | $6.11M 10-K · filed 2013-06-25 | ||||
| 2011-12-31 | $1.74K 10-K · filed 2013-06-25 | $1.74M 10-Q · filed 2012-02-21 | $3.30K derived: sum of 2 quarters · filed 2013-06-25 | $4.93M 10-Q · filed 2013-02-14 | $1.19M derived: sum of 4 quarters · filed 2013-06-25 | |||
| 2011-09-30 | $1.56K 10-K · filed 2013-06-25 | $1.56M 10-Q · filed 2011-11-14 | $3.19M 10-Q · filed 2012-11-09 | $1.19M derived: sum of 3 quarters · filed 2013-06-25 | $2.27M derived: sum of 4 quarters · filed 2013-06-25 | |||
| 2011-06-30 | $1.63K 10-K · filed 2013-06-25 | $1.63M 10-Q · filed 2011-08-15 | $1.18M derived: sum of 2 quarters · filed 2013-06-25 | $2.26M derived: sum of 3 quarters · filed 2013-06-25 | $3.38M derived: sum of 4 quarters · filed 2013-06-25 | |||
| 2011-03-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2012-06-27 | $2.26M derived: sum of 2 quarters · filed 2012-06-27 | $3.38M derived: sum of 3 quarters · filed 2012-06-27 | $4.32M 10-K · filed 2012-06-27 | ||||
| 2010-12-31 | $1.08M 10-Q · filed 2012-02-21 | $2.20M derived: sum of 2 quarters · filed 2012-02-21 | $3.14M 10-Q · filed 2012-02-21 | |||||
| 2010-09-30 | $1.11M 10-Q · filed 2011-11-14 | $2.06M 10-Q · filed 2011-11-14 | ||||||
| 2010-06-30 | $943.26K 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |